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ABSTRACT 
Oral squamous cell carcinoma is a major public health concern worldwide and a growing threat for rapidly developing economies such as India, 
where it ranks among the top three cancers. This review aims to discuss the national status of oral cancer in terms of incidences and mortality. We 
have added the emphasis on clinical characteristics of oral potentially malignant disorders and emerging optical diagnostic techniques to detect oral 
lesions which would otherwise go undetected by a conventional oral examination. Modern detection systems such as autofluorescence, 
chemiluminiscence, Narrowband imaging and Raman spectroscopy will definitely aid Conventional oral examination for diagnosis. Definitive 
diagnosis of oral cancer by using saliva and serum-based noninvasive biomarkers can minimize the need of tissue biopsies and patient discomfort. 
Urgent research efforts are required to find new ways to identify and examine high-risk population for the early diagnosis and prevention of Oral 
squamous cell carcinoma.  
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INTRODUCTION 
Ever-increasing burden of cancer becomes a major public health 
concern worldwide, posing a high impact on world health. Mortality 
due to cancer now exceeds the deaths caused by coronary heart 
diseases or all strokes [1]. International Agency of Research on 
Cancer (IARC) estimated 14.1 million new cancer incidences and 8.2 
million cancer deaths worldwide in its online database GLOBOCAN 
2012. Constant growth has been observed in cancer incidence and 
mortality, which were 12.7 million and 7.6 million, respectively in 
2008. Prevalence data indicated that 32.6 million people are living 
with cancer diagnosed in the previous five years. Estimated cancer 
incidences are expected to raise up to 20 millions in 2025 [2]. Oral 
cancer (International classification of diseases, 10th edition, ICD-10 
codes: C00–C08) ranks 15th globally with high prevalence and 
mortality in less developed countries. About 90% of oral cancers are 
oral squamous cell carcinoma (OSCC) [3, 4]. OSCC includes 
anatomical sites such as lip mucosa, dorsal, ventral, and border of 
the anterior two-third of the tongue, vestibule, gums, hard palate, 
chick mucosa and retromolar area. It shows poor prognosis and 
consistent treatment effort have not improved the 5 y survival rate, 
which is about 50-63% [5]. Additionally, oral cancer treatment 
causes disfigurement many times, affecting the patient’s quality of 
life permanently. Cancers of the lip and oral cavity accounted for 
about 300,000 incidences (2.1% of world total) and 145,000 (1.8% 
of world total) deaths worldwide. Two-third oral cancer loads have 
been found in males. 77% of the total oral cancer incidences have 
been observed in less developed regions. Non-communicable 
diseases causes 50% deaths in India among which 6% are attributed 
to cancer and are expected to rise in the near future due to 
population growth. More than 1 million cancer cases are diagnosed 
each year and projected to raise upto 1.7 million in 2035. More than 
70% deaths due to cancer occurred in productive age of individuals 
(30-69years). Age standardized incidence rate for all cancers is 94 
per 100,000 individuals [6, 7]. Incidence of OSCC in India is higher 
compared to the western world due to regional variations and 
pattern of habits. Tobacco is considered to be main causative factor 
for most premalignant and malignant lesions of the oral cavity. 
Unique indigenous tobacco preparations along with areca/betel nut 
(Gutakha, Mawa etc.), overconsumption of alcohol, poor diets, poor 
oral hygine and persistent infections of the upper aerodigestive tract 
with human papilloma virus (HPV) significantly increases oral 
cancer risk [8]. Consumption of tobacco and betel quid with 
synergistic alcohol effects are unique to India. Late appearance of 
clinical signs and symptoms of OSCC carries significant morbidity 
and mortality. A recent systematic review by Omar [9] concluded 
saliva-based oral diagnosis and optical diagnosis are promising 
noninvasive diagnostic modalities for the early detection of OSCC. 
Saliva based biomarkers can help to monitor the disease status of 
dysplasia between biopsies. Salivary diagnostics still requires 
validation [10]. While a review by Liu et al., summarizes although 
non-invasive techniques show potential for detecting OPMD 
standalone use of these techniques cannot be recommended in 
clinics [11]. Large sample size prospective studies are needed for 
screening with these tools. Similar conclusions are drawn by Iyer et 
al. [12] where they find insufficient evidence for the use of 
adjunctive optical screening techniques in routine clinical practice 
but salivary biomarkers can be a potential screening tool. Regular 
visual oral screening of high risk population also benefit in reducing 
mortality in geographic areas where OSCC is more common. 
Here, we review published data on the national status of oral cancer 
in terms of incidences, age-adjusted incidence rates (AAR), 
mortality, trends, regional variations and incidences according to 
sex in India. We have also briefly discussed the major risk factors for 
the development of OSCC with its possible implications and mode of 
action. We have also added the emphasis on clinical characteristics 
and risk factors for the development of oral potentially malignant 
disorders (OPMD). We also tried to explore the emerging optical 
diagnostic techniques to detect oral lesions that would otherwise go 
undetected by conventional oral examination. Definitive diagnosis of 
oral cancer by using saliva and serum-based non-invasive 
biomarkers will minimize the need of tissue biopsies and patient 
discomfort. 
Current status of oral cancer in India 
Oral cancer is major cause of mortality and morbidity in India. It is 
the third common cancer type next to breast and cervix cancer, 
which accounts for about 30% of the total cancer cases in the 
country. India share quarter of the world burden of oral cancer. 
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Around 77,000 new cases diagnosed and 52,000 people die each 
year due to oral cancer [13]. Cancers of Gingio-buccal complex 
(buccal mucosa, lower alveolus, retromolar trigone) comprises 60% 
oral cancer cases hence typically called as ‘Indian oral cancer’ [14]. 
National cancer registry programme (NCRP) report (NCRP 2012-
2014) summarized oral cancer as second and third most common 
cancer affecting men and women respectively. Oral cancer is the 
leading cancer type in males of western states cancer registries such 
as Barshi Rural/expanded, Ahmadabad Urban, Nagpur, Pune and 
Wardha. It is also the leading cancer type in Bhopal and second 
leading in Mumbai cancer registries. Ahmadabad cancer registry 
shows highest age incidence rate of oral cancer about 28.7 per 
100000. AAR variable nationwide and is about 20 per 100,000 
population, which is again highest in comparison with 10 per 
100,000 in the USA, and 2 per 100,000 in the Middle east. Incidences 
of OSCC are more common in men than women. Increasing trends of 
incidence rates in men of about 1.4 to 7% has been observed in 
various PBCR while it remained constant or decreased slightly in 
women. Mumbai based cancer registry showed 2.7% annual 
increase in age-standardized incidence rates of oral cancer in last 15 
y in men [15]. East Khasi Hills in Meghalaya state shows the highest 
AAR (9.4) of oral cancer in females. Estimated national mortality of 
oral cancer is 6.7 per 100,000 in men and 3 per 100,000 in women. A 
national representative field report Million Death Study (MDS) from 
1.1 million homes across the country reported oral cancer (including 
pharynx) as most common fatal cancer in men (22.9% deaths) while 
ranks fourth in women (9.8% deaths). According to GLOBOCAN 
online analysis prediction (Accessed on 29.11.2016) oral cancer 
cases in India will significantly increase from 77003 in 2012 to 
94903 (66025 males and 28878 females) in 2020. Mortality due to 
oral cancer is also likely increase from 52067 in 2012 to 64245 
(44492 males and 19753 females). Urgent efforts are required to 
educate people about the established risk factors of OSCC. 
Otherwise, this situation will further get worsen and may transform 
into oral cancer epidemics in India.  
Oral potentially malignant disorders (OPMD) 
OSCC is a result of malignant transformation from precancerous 
lesions caused due to various environmental factors. Precancerous 
lesions of oral mucosa are altered areas of tissues which have 
undergone malignant change during follow up. These premalignant 
phases show some chromosomal, genomic and molecular alterations 
found in clearly invasive oral cancers [16, 17]. These are termed 
‘epithelial precursor lesions’. Clinicians are well versed about 
characteristic clinical presentation and risk of malignant 
transformation of pre-cancerous lesions. But general population is 
largely unaware about symptoms and consequences of precancerous 
lesions. There is an urgent need to educate people to seek treatment 
in the early stage [18]. Pathologic findings have limitations in 
predicting risk of malignant transformation of OPMD and specify the 
need of molecular markers, which can truly predict the risk of 
malignant transformation.  
Leukoplakia 
Oral leukoplakia (OLP) is most common premalignant lesion having 
wide risk of malignant transformation ranges from 0.13 to 34% [19]. 
Global prevalence rate ranges 0.5 to 3.4%. Smoking is high-risk 
factor while alcohol, HPV infection, candidiasis and lowered vitamin 
A and beta carotene are also found to be possible risk factors in the 
development of OLP [20]. Variable incidence rates have been 
observed in India according to tobacco chewing practices. Bihar has 
0.2%, Andhra Pradesh has 4.9% while Gujarat has 11.7% prevalence 
[21]. It can be defined as white plagues of questionable risk having 
excluded (other) known diseases or disorders that carry no 
increased risk for cancer. It show atrophy or hyperplasia 
(acanthosis) and may or may not demonstrate epithelial dysplasia 
and have assessable tendency to malignant transformation. It is 
found in the oral cavity, lip vermilion, buccal mucosa and gingival. 
Clinically leukoplakia shows two types as homogenous and non-
homogenous. Homogenous leukoplakia shows low risk of malignant 
transformation, while non-homogenous leukoplakia carries higher 
risk of malignant transformation. Non-homogenous leukoplakia 
includes three varieties-Speckled leukoplakia is a mixed white and 
red lesion but retaining red character. Nodular leukoplakia is a 
rounded red or white excrescence while verrucous leukoplakia 
shows wrinkled or corrugated surface appearance. Proliferative 
verrucous leukoplakia (PVL) is an aggressive form of oral 
leukoplakia having considerable morbidity and strong potential for 
malignant transformation [22]. PVL generally afflicts old age 
population over 60 y. Many cases of PVL are resistant to all forms of 
treatments like laser microsurgery, surgical excision and radio and 
chemotherapy. Smokers carry six times more risk of development of 
oral luekoplakia than non-smokers, while alcohol is also a major risk 
factor [23].  
Erythroplakia 
Oral erythroplakia (OE) presents as a bright red velvety plaque, 
which cannot be defined clinically or pathologically. When this red 
patch has white areas within or surrounding it is termed as 
erythroleukoplakia [24]. Incidences of oral erythroleukoplakia are 
rare (0.2-0.8%) occurs most commonly in middle-aged and older 
men [25]. Although uncommon (prevalence 0.02-0.2%), OE shows 
very high malignant potential, which is about 44.9%. Large 
population based studies are required to obtain actual prevalence. 
Biopsy examination revealed 91% OE was dysplasia, carcinoma in 
situ or cancer. Tobacco chewing is the strong risk factor in Indian 
population (OR-19.8) with a strong dose response relationship for 
frequency and duration [26]. Histopathological examination of OE is 
the only method that can be used to evaluate if there is concomitant 
dysplasia, carcinoma in situ, or carcinoma within erythroplakia, 
which is also the same for oral leukoplakia. Before a surgical biopsy 
is conducted, epithelial status is generally not known. It has been 
shown that endoscopic technique helpful in detecting early 
cancerous lesion in the upper aerodigestive tract, including 
esophagus, pharynx, and oral cavity; abnormal vascular 
architectures of oral mucosa appear as increased number, tortuous, 
dilated, twisted, elongated, and corkscrew-type small blood vessels 
of varying caliber [27] showed that twisted elongated and 
destructive patterns of intraepithelial microvasculature of 
endoscopic images are crucial indicators for detecting high-grade 
dysplasia, carcinoma in situ, and invasive carcinoma in OE.  
Lichen planus 
Lichen planus (LP) is T-cell mediated chronic inflammatory disorder 
that affect skin and mucous membranes. Oral Lichen Planus (OLP) is 
an autoimmune disease of unknown etiology in which local 
recruitment of CD 8 T lymphocytes induce apoptosis of basal 
epithelial cells. OLP affects 0.5 to 2.6% of general population [28]. In 
Indian population, incidence rate of OLP is 2.6% with incidence 
prevalence in females [29]. It carries risk of malignant 
transformation unlike to that of cutaneous lichen planus. Calculated 
risk of malignant transformation of OLP is approximately 1.63% 
after 6 y of initial diagnosis [30]. Reticular, erythematous (atrophic) 
and erosive (ulcerated, bulbus) are clinical subtypes recognized for 
OLP. Atrophic and erosive clinical subtypes are characterized by 
mild burning to intense pain which may interfere swallowing and 
speaking abilities of the affected individual while reticular subtype 
lesions are asymptomatic [31]. OLP is commonly seen on the buccal 
mucosa as well as it manifests the tongue, gingival or mucobuccal 
fold. Reticular lichen planus (RLP) shows high occurrence followed 
by erosive form. Stress and various systemic illnesses importantly, 
hypersensitivity reactions are associated with OLP. It can be 
diagnosed correctly by clinical manifestations however, clinical 
diagnosis is confirmed by oral biopsy with histopathology to rule out 
dysplasia and malignancy. 
Oral submucous fibrosis 
Muthubabu K [32] defined Oral submucous fibrosis (OSF) is a 
disease with unknown aetiology and is a legacy of Indian 
Population. OSF is characterized by abnormal accumulation of 
collagen fibre in the oral submucosa. Habit of betel nut or areca nut 
chewing, prolonged irritation due to tobacco and chillies may be 
causative factors for OSF. Vitamin B deficiency and Iron deficiency 
has also been noted in patients with OSF [33]. Early forms of OSF are 
shows clinical symptoms such as burning sensation, vesiculation, 
blanching of mucosa and leathery mucosa while late forms are 
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presented with fibrous bands within mucosa, narrowing of 
oropharyngeal orifice, woody changes to mucosa and tongue and 
limitation of mouth opening. 
Oral squamous cell carcinoma (OSCC) 
OSCC accounts for more than 90% of cancers of oral cavity and 
oropharynx. It is a malignant condition of oral mucosal epithelium 
occurs at any anatomical site in the oral cavity. It has ability of local, 
regional and distant spread. Invasive cancers shows clinical 
symptoms such as persistant ulceration, tissue proliferation or 
destruction, red and white color varieties, progressive growth of the 
area affected, pain, and loss of function etc. OSCC shows one or more 
clinical symptoms of invasive cancers that can be detected by 
routine examination [34]. Possible triggering factors for OSCC are 
exposure to tobacco, alcohol and HPV. Role of human papilloma 
virus (HPV) in carcinogenesis of OSCC seems to be very minimal. 
Several studies provide circumstantial evidence of a significant 
epidemiological association between Epstein–Barr virus (EBV) and 
OSCC. Tongue cancer in young patient without exposure to tobacco, 
alcohol and HPV has a distinct genetic profile such as mutations of 
tumour suppressor genes p53 [35]. Annertz K et al. [36] shown the 
increasing incidence of OSCC in young patients is mainly associated 
with an up to 6-fold increased occurrence of tongue carcinomas.  
Detection methods 
Despite the fact that oral cavity is easily accessible for routine 
examination of oral lesions majority of OSCC patients are diagnosed 
at a late stage and shows recurrence of cancer after initial treatment 
in those with lymph node metastasis [37]. 5 y survival rate of OSCC 
patients remained low since past few decades. High mortality is 
often associated with delayed diagnosis. Five year survival rate is 
about 80% to 85% at early stage diagnosis and reduced to 50% at 
late stage presentation [38]. Detection of precancerous lesions in 
susceptible population can significantly reduce the incidences of OSCC. 
Traditional methods such as visual conventional oral examination 
alone or by using aids such as vital stains are still proved to be 
economical and effective. Sensitive detection techniques for the OSCC 
and OPMD have been summarized in table 1. 
Table 1: Summary of diagnostic methods for OPMD and OSCC 
Category  Diagnostic method Method of analysis 
Clinical methods *Conventional oral examination 






Visual examination of oral cavity with incandescent light [35]. 
Visual examination of oral cavity with incandescent light. 
After TB staing for the presence of dark blue (malignant) and pale blue (OPMD) area [36]. 
Scanning of oral cavity for the presence of dark areas illuminated with 400-460 nm 
wavelength light [37]. 
Scanning of oral cavity for the presence of aceto-white areas [38]. 
Computed IPCL pattern analysis of oral lesions. 
Generation of Raman Spectroscopy subjected to computer analysis [7]. 
Microscopy *Histopathology
*Cytopathology
Microscopic examination of tissue for the assessment of epithelial dysplasia [40]. 
Microscopic examination of disaggregated cells for the assessment of cellular dysplastic 
changes [4]. 
Modern detection techniques are relatively expensive and associated with controversial diagnostic outcomes but still have potential to improve 
diagnosis of OPMD and OSCC.  
Conventional oral examination (COE) 
Conventional oral examination with thorough history by healthcare 
professionals regularly for all patients’ especially high-risk 
individuals is an effective early detection technique. A huge cluster 
randomized controlled screening trial of high-risk population 
initiated in 1996 in Kerala, India. Screening group (n=96 517) and 
the control group (n=95,356) were followed up by oral visual 
examination for the period of 15 y. Screen positive individuals were 
referred to the study clinicians. Interim reports [39, 40] published 
out of this study reported that regular oral visual screening in high-
risk individuals can significantly reduce oral cancer mortality. 15 y 
follow up with 3 to 4 rounds of visual screening in and/or alcohol 
users reduced 47% incidence mortality by 81% [41]. Visual oral 
examination with normal light is the effective conventional method 
at least for some anatomical sites. Oral lesions should be carefully 
observed for its size, colour, texture and outline. White, red and 
white, ulcerated and/or indurated lesions needs special attention. 
Various tools such as Toluidine blue, cytopathology and optical 
imaging systems are used for the confirmation of suspicious oral 
lesions [38]. Routine oral examination is proved to be effective 
means of detection of precancerous lesions and OSCC at early stage 
as incidences of oral cancer are high in India. 
Toluidine blue 
Toluidine blue (TB) staining is an easy, inexpensive and non-
invasive tool being used traditionally for the detection of 
premalignant and malignant lesions of the oral cavity. TB is a 
metachromatic dye that stains acidic components of cells. It binds 
phosphate bonds and intensity of staining depends on amount of 
DNA which is again proportional to number of nuclei present in the 
cells of superficial layers. Dark blue stained lesions are considered to 
be malignant while premalignant lesions appear pale blue [43]. TB 
staining test for oral lesion includes 20 second oral pre rinse of 1% 
acetic acid, 20 second water rinse followed by TB solution rinse. It is 
then followed by post rinse of 1% acetic acid and water rinse [44]. 
Inflammatory lesions and healing ulcers may get stained dark blue 
and produces false positive results. Patient follow up reduces false 
positive interpretation of such lesions. However, clinical expertise 
and training also fluctuates the outcomes of the test. But still TB is 
proved to be an efficient diagnostic aid which helps clinicians for the 
patient referral to expert health care providers for proper diagnosis 
and treatment.  
Histopathology 
Incisional and excisional biopsy followed by staining and 
microscopic examination by pathologist is the gold standard for the 
diagnosis of OPMD and OSCC. It allows assessment of severity of 
epithelial dysplasia as mild, moderate and severe which is an 
important prognostic indicator. However, removal of biopsy is an 
invasive procedure. Identification of early neoplastic changes and 
pre-cancerous lesions are associated with high interobserver 
variations [45].  
Cytopathology 
Brush cytology and scalpel biopsy are current diagnostic approaches 
for oral cancer (FDI world dental federation, 2015). Brush cytology 
is a less invasive method which enables examination of 
disaggregated cells of mucosal epithelial tissue under light 
microscope. Despite its less specificity, it is commonly practiced 
technique in the clinical setting for patients in which scalpel biopsy 
is not advisable and for follow up of diagnosed lesions. Oral CDx 
system is less invasive computer assisted cytomorphometric 
analysis tool for brush biopsies. Transepithelial cell and tissue 
samples are collected by using specialized disposable brush and 
fixed on glass slides. Samples are stained with modified 
Papanicolaou test (Pap test). Computer based image processor 
 Kshersagar et al. 
Int J App Pharm, Vol 12, Special Issue 4, 2020, 1-10 
International Conference On Cancer Biology: Basic Science to Translational Research (CBTR 2020)                                                                            | 4 
analyses scattered cells for their abnormal morphology with high 
precision. Samples with no epithelial abnormality are reported as 
negative, with abnormal epithelial changes as atypical and with 
definitive dysplastic changes as positive. Atypical and positive 
patients have to be reffered to undergo incisional biopsy for 
definitive diagnosis. However, Oral CDx system is a much expensive 
cytology technique and attracted controversies by producing false 
negative results [46].  
Light based detection systems/Optical diagnostics 
Traditional visual, oral examination limits non-specialists in the field 
to identify premalignant and malignant oral lesions and may results 
in false negative/positive and may cause further referral and 
treatment delay. Modern optical diagnostic systems are currently 
improving to overcome this limitation [47]. Optical diagnostics 
systems detect changes in the optical properties of neoplastic tissues 
in oral cavity caused due to metabolic and structural changes during 
the process of transformation. Modern optical systems based on 
autoflurescence, chemiluniscence, narrow band imaging and Raman 
spectroscopy are gaining clinician’s attraction as a method for the 
diagnosis of oral cancer. Optical diagnostic visualization aids reduce 
patient discomfort and pain caused due to invasive procedures.  
Fluorescence visualization (FV) 
Pathological differentiation of premalignant lesions for their 
potential malignancy is still challenging. It needs clinical and biopsy 
examination which is an invasive process. Fluorescence guided 
examination of oral cavity is emerging as a non-invasive tool for 
identification of potentially malignant and malignant lesions. It is 
based on the differential scattering of light by cellular components 
upon excitation with specific wavelength of light. SCC and high-
grade dysplasia can be distinguished from normal tissue with high 
sensitivity with FV but less specific in identifying low-grade 
dysplasia [48]. Many molecules naturally present in the cells such as 
nicotinamide adenine dinucleotide (NADH), Flavin adenine 
dinucleotide (FAD), collagen, tryptophan, elastin, keratin, 
haemoglobin etc. shows autoflurescence when irradiated with 
specific wavelength of light. These fluorophores have specific 
excitation and emission wavelengths. Their altered concentration 
and change in fluorescence pattern can be detected in potentially 
malignant lesions. Visually Enhanced Lesion Scope (VEL scope) is 
WHO endorsed and US FDA approved device used by many dentists 
worldwide. It emits blue light (400-460 nm wavelength), causing 
pale green oral cavity auto fluorescence. Normal oral mucosa display 
pale green florescence while abnormal tissue appears dark as a 
result of phenomenon called a loss of auto fluorescence (LAF). 
Clinician can then examine oral cavity effectively for the changed 
florescence pattern in doubtful lesions [49]. This method is non-
invasive, safe and reduces biopsies and use of dyes. A literature 
study shows the specificity of device ranges from 30% to 100% in 
detecting malignancy and dysplasia. But controversies have been 
observed to use VEL scope as a routine diagnostic aid for new cases 
as it is associated with false positive diagnosis ranging from 15-81% 
which leads to over referrals and increases patient anxiety. Clinically 
benign lesions show LAF many times when observed with VEL scope 
leads to over referrals. LAF is not observed with VEL scope in lip 
moderate dysplasia and increases chances of false negative 
diagnosis, which is more worrisome false positive diagnosis with 
VEL scope can be reduced by keen clinical interpretation and 
periodic review of patient [50].  
Chemiluminescence 
Chemiluminescence is described as emission of light from a chemical 
reaction. Use of chemiluminiscent devices for head and neck regions 
was approved by US FDA in 2002. This technology is marketed as 
ViziLite and ViziLite Plus Systems and MicroLuxTM/DL systems. 
This device is a capsule consists of outer flexible plastic coat having 
fragile glass vial inside. Bending the capsule would results in a 
reaction between acetyl salicylic acid and hydrogen peroxide. This 
reaction produces blue-white chemiluminiscence of 430-580 nm 
wavelength, which lasts for 10 min. All three methods require oral 
acetic acid rinse for 1 min. which removes surface glycoproteins and 
causes cellular dehydration. Normal cells of buccal mucosa absorb 
blue light while dysplastic cells having high nuclear/cytoplasmic 
ratios reflect light and appear ‘aceto-white’ [51]. ViziLite can 
effectively detect malignant lesions. More correct diagnosis of lateral 
spread of lesion could be possible with ViziLite than clinical 
examination alone [52]. However, chemiluminiscence detection 
method has many limitations. It can effectively detect leukoplakias 
but failed to detect erythroplakias. False positive and false negative 
results produced by this method are a matter of worry. It is 
expensive and needs dark environment for observation. Permanent 
record cannot be generated except photography. Depth of the lesion 
cannot be predicted, which is an important determinant of 
malignancy [53]. Chemiluminiscence detection is less specific for the 
detection of premalignant lesions and may leads to misdiagnosis in 
the hands of the general dental practitioner. 
Narrow band imaging (NBI) 
Abnormal angiogenesis is characteristic feature of all types of 
tumors. As a result of metabolic stress, tumor recruit surrounding 
endothelial cells and blood vessels for the development of new blood 
vessels, a process called as neoangiogenesis. Metabolic requirements 
are fulfilled by the formation of new blood vessels from the 
preexisting blood vessel. New blood vessels are dilated shows 
excessive branches and openings and improper basement 
membrane [54]. Narrow Band Imaging (Olympus Medical Systems 
Corporation, Tokyo, Japan) is a fiberoptic endoscopic visualization 
aid initially used for the gastrointestinal tract. It has also used for 
aerodigestive and urinary tract. Recently it is used for the diagnosis 
of OPMD and OSCC of the oral cavity. Working principle of the device 
is based on differential tissue penetration properties of light of 
different wavelengths. It enhances abnormal morphology and 
vasculature of mucosa and submucosa. Two optical filters in NBI 
mode select blue and green narrow bands of light with 450 and 540 
nm wavelengths, respectively. Absorption peak corresponds to 
haemoglobin, thus highlighting the capillary bed and interpupillary 
capillary loop (IPCL). Blood vessels in the superficial layer appear 
brown while those in the deeper layer appear cyan enhanced by 
green light. Reflected light is captured by charge-coupled device 
(CCD) to produce NBI image [55]. Characteristic patterns of IPCL in 
leukoplakia, erythroplakia, chronic non-healing ulcers premalignant 
and malignant oral lesions can be effectively diagnosed with the help 
of NBI [56–58]. NBI is an effective aid for diagnosis of deeper 
potentially malignant lesions which is not possible with the help of 
normal white light. NBI is also effective (77%) for the diagnosis of 
second primary malignancies after surgery. Second primary 
malignancies can be detected in early stages which minimize the 
need of radical Surgery. Thus NBI will definitely helpful to improve 
functional outcomes if second primary tumors are diagnosed early 
[59]. NBI is certainly a prominent non-invasive visualization aid in 
the diagnosis of OSCC. 
Raman spectroscopy 
Professor Raman of Calcutta University discovered Raman effect for 
which was awarded with Nobel prize in 1930. When light interacts 
with matter most photons pass through it unchanged while some 
interacts with molecules in the matter. Only a tiny portion of 
photons among these (1 in 106-108) show phenomenon of inelastic 
scattering and discharge from material at a different wavelength 
called as Raman Effect. Lasers and charged coupled devices (CCDs) 
made possible the Raman spectroscopy (RS) of tissues possible by 
collecting weak Raman signals. RS is based on Raman effect which 
differentiates biological specimens on the basis of molecular details. 
RS is a high precision optical technique based on inelastic scattering 
of light by illuminating molecules. This non-invasive technique does 
not require use of reagents and dyes. It generates Raman spectrum 
based on molecular characteristics of the tissue and assigns 
characteristic peak to the corresponding molecule present in the 
tissue. It can be used in UV, visible and near-infrared wavelengths 
[60]. High spectral resolution at the molecular level enables 
detection of the exact location and borders of the lesion. Literature 
study showed in vivo and ex vivo use of RS. RS spectrum has been 
studied in exfoliated cells, cancer tissues and body fluids such as 
serum and plasma. Study conducted using portable Raman 
spectrometric instruments of the oral cavity using histopathology as 
a gold standard gives 94% specificity in discriminating normal tissue 
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from premaligant and malignant oral tissue [61]. Use of RS for ex 
vivo diagnosis of OPMD and OSCC by using a serum is minimally 
invasive and comfortable especially to screen high-risk population. 
Sahu et al. [62] found intense positive peaks of Raman spectra 
signifying high levels of DNA and proteins in the serum sample of 
buccal cancer and in situ tumor patient with respect to normal. In 
vivo RS analysis showed dominated protein bands in Raman spectra 
of OSCC. Premalignant lesions also showed a similar type of spectra. 
It is not possible to differentiate premalignant lesion from malignant 
on the basis of Raman spectra. Habitual tobacco users showed 
deviation from healthy control spectra [59]. RS spectra were 
obtained by using plasma, urine and saliva of healthy individuals, 
OSF, leukoplakia and OSCC patients. It discriminates OPMD and 
OSCC from normal control with significant accuracy of 78%, 90.5%, 
93.1% and 97.4 % for blood, urine, saliva and tissue samples 
respectively [60, 61]. Dedicated instrument and stringent laboratory 
conditions limits the use of RS in large population screening. 
Biomarkers of OSCC and OPMD 
Cancer biomarkers are identifiable signature molecules produced by 
cancer cells or other cells in response to transformation and cancer 
development which could be useful for early diagnosis, prognosis, 
disease progression monitoring and treatment response. Various 
biomolecules such as DNA, mRNA, proteins, metabolites, mi-RNAs 
etc. act as a biomarker. The advancements in treatments of oral 
cancer such as surgery, chemotherapy and radiotherapy are not 
proven to be successful in the improvement of five-year survival rate 
of oral cancer patients, which is well below 50% [66]. This failure 
can be explained by late stage presentation of oral cancer. Classical 
Tumor, node and metastasis (TNM) classification is the basis for 
treatment planning and prognosis for OSSC in routine clinical 
practice which is insufficient to predict clinical outcomes in OSCC 
patients [67]. Precancerous lesions often go unidentifiable clinically 
only some are recognized as erythroplakia/leukoplakia etc. 
Malignant progression of such lesions requires years hence 
precancerous lesions are attractive targets for screening. 
Histopathological grading shows limitations in predicting risk of 
malignant potential and reliable prognostic markers are lacking for 
OSCC. Molecular analysis of such lesions has potential to predict risk 
of malignant transformation. Cancer research has revealed that 
there is a link between molecular and tissue-level changes that make 
malignant changes in the tissue causing disease progression. 
Biomarkers play a major role in distinguishing the presence or 
absence of disease. The “biomarker” is a biological molecule found in 
blood, body fluids, and tissues that is a sign of a condition of disease 
such as cancer. The biomarkers are classified on the basis of 
proteomics, genomics, metabolomic and Immunohistochemistry 
technique (fig. 1). 
 
 
Fig. 1: Classification of oral cancer biomarkers 
 
It include proteins, nucleic acids, peptides, enzymes, antibodies, 
metabolites, lipids, and carbohydrates. Biomarkers can be derived 
from one or a combination of the body fluids blood, serum, plasma, 
body secretions, stool, urine. Obtaining body fluids sample for 
biomarker investigation can be non-invasive, minimally invasive or 
least invasive. DNA/RNA extracted from blood, saliva will help to 
correlate and confirm the diagnosis, monitor the disease 
progression, or act as prognostic indicators in treatment. Early 
diagnosis and treatment of oral cancer can improve patient survival, 
which requires biomarkers that can be employed in routine clinical 
practice.  
Proteomic techniques 
Non-invasive detection methods are emerging as promising tools for 
the early detection of OSCC. Blood and saliva-based proteomic 
profiling is less invasive new practical approach. These body fluids 
are easily obtainable and contain characteristic biochemical 
signature molecules shed by oral lesions allowing detecting as a 
potential biomarker. Modernization of proteomic analysis 
techniques mass spectroscopy, liquid chromatography and protein-
peptide labeling techniques identify salivary proteins with great 
precision. Proteins such as α-amylase, albumin, cystatins, hystatins, 
secretory-IgA, lactoferrin, mucins, lysozymes, proline-rich proteins, 
statherin and transferrin constitute 98% of total salivary proteins. 
Proteomic profiling of saliva from OPMD, OSCC and healthy 
individuals by means of SDS-PAGE coupled with LC-MS/MS 
identified around 1000 salivary proteins. Among them, 22 proteins 
are overexpressed in OSCC patients than healthy and OPMD group. 
Elevated Salivary Resistin (RETN) shows strong correlation with late 
stage primary tumors and could be a potential salivary biomarker 
for OSCC detection [68]. Enolase 1 have been significantly higher in 
saliva of OSCC suggesting its use as a biomarker [69]. Serum protein 
biomarkers are helpful for the assessment of the aggressiveness of 
tumors and lymph node metastasis. In research analysis levels of 
various serum proteins fibronectin, gelsolin, angiotensinogen (AGT) 
and Heptoglobin (HP) have been validated in node-positive tumors 
and negative tumors. These proteins are differentially expressed in 
node-positive and negative tumors [70].  
The proteomic analysis of high throughput LC–MS/MS revealed the 
presence of 1256 proteins in saliva of a healthy individual. Out of 
total 3449 proteins, 139 salivary proteins have shown to be 
differentially expressed in oral cancer [71]. Liu et al. [72] validated 
30 overexpressed proteins in OSF and OSCC tissues. Annexin A4 
(ANXA4) and Filamin-A (FLMA) proteins are consistently 
upregulated while Fibrinogen alpha chain precursor (FGA) was 
downregulated from normal buccal mucosa tissue to OSF and OSCC, 
which shows prognostic significance. However, large multicentric 
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studies are required for the detailed investigation of this attractive 
method of OSCC biomarker investigation.  
Genomic technique 
Micro RNAs (mi-RNAs) 
Mi RNAs are small non-coding RNAs (17–22 nucleotides in length) 
that regulate post-transcriptional gene expression during 
development, cell proliferation, metabolism and signal transduction 
by degradation of mRNAs. Mi RNAs have been studied extensively in 
serum, plasma, saliva, formalin-fixed and paraffin-embedded tissues 
(FFPE) and cell lines of OSCC as a potential biomarker. The presence 
of various types of circulating mi RNAs and its association with 
cancer manifestation, invasion and metastasis have been studied in 
various types of cancers [73]. Circulating miR-196a and miR-196b 
levels are significantly elevated in oral cancer and precancerous oral 
lesions. Combined detection of miR-196a and miR-196b can be a 
potential oral cancer panel plasma biomarker for early detection 
[74]. Plasma miR-223 levels increases in postoperative patients in 
which tumor relapsed in 6 mo. So, miR-223 is helpful for treatment 
monitoring and as a prognostic biomarker [75]. 
MiRNA profiling of OSCC patient’s saliva high lightened its 
importance as a potential diagnostic biomarker for oral cancer. miR-
125a and miR-200a levels are lowered in oral cancer patient saliva. 
miR-21,-31,-107,-138,-504,-10b, miR-16,-20a,-106b,-142-3p, miR-
155,-423,-451, and let-7i levels are upregulated while miR-10a,-
125b,-375 levels are down-regulated in formalin-fixed and paraffin-
embedded tissues of squamous cell carcinomas [76]. Elevated miR-
155 level is associated with tobacco chewing/betel quid habit in a 
RT-qPCR analysis of OSCC tissues of Indian patient study [77]. miR-
1246 expression is increased in OSCC cell lines and tissues. Its high 
expression leads to poorer prognosis of OSCC patients, which 
suggests its importance as a promising prognostic biomarker [78]. 
miR-203 and miR-205 are uniformly expressed in lymph nodes of 
metastatic OSCC. Expression of these molecules can be evaluated in 
fine needle aspirate (FNA) biopsies for diagnostic purpose, sentinel 
lymph node examination during surgery, entire lymph node analysis 
after surgery along with histopathology as well as for patient follow 
up [79]. Many oncomiRs and their target m-RNAs have been studied 
as it acts as tumor suppressor miRs. OSCC Cell line study of the 
expression of MiR-494 revealed that it is emerging as a tumor 
suppressor miRNA as it repress the expression of HOXA 10 which is 
upregulated in OSCC [80]. MiR-506 target transcription factor GATA 
binding protein 6 (GATA6) and suppress the growth of tumor. It is 
downregulated in OSCC tissue and cell lines and is a attractive 
therapeutic target as its restoration is associated with tumor 
suppression. MiR-128 inhibits m-RNAs of H3f3b, BMI-1, PAIP2, BAG-
2, and BAX. Overexpression of MiR-128 accelerates the apoptosis 
and inhibits cell proliferation of HNSCC (Head and Neck Squamous 
Cell Carcinoma), which suggests the clinical value of miR-128 as a 
therapeutic target [81]. Proto-oncogene Yes-1 (Tyrosine-protein 
kinase) expression is increased in cancer. Its upregulated expression 
is associated with tumor aggressiveness. MiR-203 suppress Yes-1 m-
RNA and protein in oral cancer cells and induce apoptosis [82]. 
TNF-LTA Single nucleotide polymorphism 
Various cytokines such as tumor necrosis factor (TNF)-α, TNF-β and 
lymphotoxin-αá (LTA) plays a role in the process of inflammation 
and tumor. These cytokines are encoded by TNFA and LTA genes 
located in the major histocompatibility complex (MHC) genes. A 
novel study in Indian patients with OSCC has identified two 
haplotypes of TNFA-LTA genes, which increases oral cancer risk. 
Patients with these haplotypes are genetically susceptible for oral 
cancer. It is a possible explanation for tobacco users who do not 
develop oral cancers. These genetic factors plays role along with 
environmental risk factors of OSCC and potential novel biomarker to 
calculate the predisposition of oral cancer in tobacco users [83]. 
Immunohistochemistry based biomarkers  
Human papillomavirus (HPV) associated biomarkers 
OSCC can be classified as HPV related and unrelated and shows 
different genetic and prognostic characteristics. Molecular 
signatures of HPV can be detected as HPV biomarkers which are 
helpful for management of OSCC patients. Immunohistochemistry 
(IHC) detection of p16INK4Ais well-established biomarker for HPV 
infection in OSCC. pRb inactivation by HPV E7 protein results in 
upregulation of CDKN2A gene which encodes cyclin-dependent 
kinase (CDK) inhibitor p16INK4A[84]. Various molecular techniques 
with different specificity and sensitivity such as PCR, quantitative 
reverse transcription PCR, Southern blotting, dot blot hybridization, 
hybrid capture and in situ hybridization have been employed to 
detect HPV DNA in OSCC tissues and exfoliated cells [85]. 
Immunohistochemical detection of p16INK4A along with detection of 
HPV DNA is the gold standard for the detection of HPV in OSCC. 
p53  
p53 is tumor suppressor gene found to be deregulated in many 
types of cancers, including oral cancer. p53 is regarded as 
‘Guardian of the genome’ which regulate cell cycle progression, 
cellular differentiation, apoptosis, DNA repair and maintain 
genomic stability. Immunohistochemical localization of p53 
protein in normal tissues is difficult due to its high catabolic 
rate; however, its mutated version has a lower catabolic rate and 
tends to accumulate in the cells [86]. HNSCC with non-functional 
p53 are associated with increased resistance to conventional 
chemotherapies and radiation [87]. 50% oral cancer as well as 
leukoplakia/erythroplakia patients, shows p53 gene mutation 
and overexpression. p53 expression is positively correlated with 
the degree of dysplasia. Severely dysplastic lesions overexpress 
p53 than lesser dysplastic lesions. Dysplastic lesions with p53 
overexpression shows high rate of malignant transformation 
[88].  
Cyclin D1 
Cyclin D1 gene (CCND1) encodes nuclear protein cyclin D1, a key cell 
cycle regulator that binds with cyclin-dependent kinases (CDK) 4 
and 6. CDK 4/6 phosphorylate retinoblastoma protein (pRb) leads to 
its functional inactivation, which allows cell cycle progression from 
G1 to S. Cyclin D1 overexpression leads to loss of cell cycle control 
ultimately causes tumor genesis [89]. In a comprehensive meta 
analysis Zhao et al. [90] have found a significant positive correlation 
between overexpression of cyclin D1 with poor prognosis and 
detrimental clinicopathogical outcome. Its expression increases with 
increased tumor size, lymph node metastasis, tumor differentiation 
and clinical stage.  
Epidermal growth factor receptor (EGFR) 
EGFR is a transmembrane tyrosine kinase receptor that regulates 
cell differentiation and proliferation. It binds epidermal growth 
factor (EGF) and transforming growth factor-alpha (TGF-α) and 
activate protein tyrosine kinase signaling. EGFR is expressed in low 
amounts in normal squamous cells [91]. EGFR overexpression in 
OSCC is caused due to amplification of proto-oncogene EGFR located 
at 7p12. It results in the proliferation and survival of cancer cells 
[92]. Overexpression of EGFR shows poorer prognostic outcomes in 
OSCC patients [93]. Sarkis et al. [94] have found EGFR expression in 
87.5% cases and found a strong correlation with lymph node 
metastasis. Indian population-based study revealed positive EGFR 
signals in all OSCC and leukoplakia cases. EGFR expression has been 
lowered in leukoplakia tissue than OSCC [95].  
Vascular endothelial growth factor (VEGF) 
Angiogenesis is a hallmark of many cancers believed to stimulate 
tumor growth. VEGF is an angiogenic stimulator and also a 
prognostic predictor in OSCC. It is a dimeric glycoprotein having a 
molecular mass 34-42 kDa. Various normal and transformed cells 
secrete VEGF after growth factor stimulation and under hypoxic 
conditions. It is found in the tumor microenvironment, which 
results in tumor angiogenesis as well as induces endothelial cell 
proliferation, migration and survival [96]. 70 % OSCC tissues and 
63.4% OPMD tissues showed positive immunohistochemical 
expression of VEGF. Higher expression has been observed in OSCC 
patients with lymph node metastasis, while controls tissues did 
not showed positive expressions [97].  
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Matrix metalloproteinase (MMPs) 
Tumor cells detach from main tumor population, migrate and grow 
at secondary sites called as metastasis. Metastasis and tumor 
recurrence causes 90% mortalities in cancer patients. MMPs plays 
very important role in the process of metastasis by degrading 
components of extracellular matrix [98]. MMPs are extracellular zinc 
mettaloenzyme family of proteins comprises 24 members which 
took part in normal development and healing process. Three 
subgroups of MMPs Gelatinases (MMP-2 and-9), stromelysins (MMP-
3,-10,-11), collagenases (MMP-1 and-13) are involved in the 
metastasis of OSCC. Increased expression of MMP1, MMP2, MMP3 
and MMP9 have been observed in OSCC cancer tissue than normal. 
Therefore, Expression of MMPs have been studied as a potential 
biomarker for the assessment of tumor recurrence in primary 
cancers, including OSCC [99].  
CD44  
CD44 is a transmembrane glycoprotein that plays an important role 
in cell growth, adhesion, differentiation and motility. It is 
successfully used as a cancer stem cell marker to isolate cancer stem 
cells in various solid tumors. Inconsistent CD44 expression has been 
observed in OSCC. Savant et al. [100] have found that the expression 
of CD44 is elevated in OSCC with the increasing grades. However, it 
could be a useful prognostic marker in combination with oct4 and c-
myc rather than CD44 alone. It is found to be overexpressed in 
cervical premalignant lesions and cervical carcinoma and effectively 
differentiates them with high sensitivity [101]. Soluble CD44 
(solCD44) and total protein levels are significantly associated with 
the development of oral cancer in high-risk individuals. ELISA 
analysis of CD44 and total protein assay from oral rinses can be a 
predictive biomarker in the development of oral cancer [102].  
Major complex class I-related chain A/B  
Major Histocompatibility Complex Class–I chain-related antigen A 
and B (MICA/B) are the surface antigens expressed by all nucleated 
cells. MICA/B presents protein fragments of cytosol and nuclear 
origin at the cell surface called antigen representation. MICA/B are 
highly polymorphic proteins induced in stressed, damaged and 
transformed cells and gives ‘kill me’ signal to NK, CD8 and γδ T cells 
by natural killer group 2D (NKG2D) receptor engagement. These 
molecules act as ligand for many immune cells and proposed to play 
an important role in tumor immunosurveillance. MICA/B is 
upregulated in response to various cellular stress stimuli such as 
CMV infection, inflammation or malignant transformation. They are 
shown to be expressed by epithelial tumor cells of the lung, colon 
and renal. MICA/B are the ligands of NKG2D receptors present on 
the natural killer andT cells (fig. 2). 
Fig. 2: Hajor histocompatibillty complex classs-1 chain related antigen A and B 
Binding of NKG2D with MICA activates the NK cells, co-stimulates γδT 
cells and CD8+T cells. The MICA-NKG2D system participates in 
epithelial tumor immune surveillance. Many tumours have evolved 
stratergies to evade the immune system by MIC shedding from cell 
surface. Endopeptidases called as metalloprotenases are responsible 
for the cleavage of MICA α1α2α3 domain in many tumor cell lines [99]. 
In a large sample size study of about 512 individuals carried out by 
Stefan Holdenrieder et al. revealed significantly higher levels of sMICA 
in sera of malignant cancer patients (161 pg/ml) while intermediate 
sMICA levels (84 pg/ml) have been observed in patients with benign 
diseases. Healthy individuals exhibited lower levels of sMICA (30 
pg/ml). sMICB levels did not differ significantly from normal control 
but significantly increased in stage IV OSCC [100]. 
CONCLUSION 
OPMD such as luekoplakia and OE have high malignant 
transformation potential. Indigenous tobacco habits can be linked to 
the development of OPMD. There is an urgent need to establish 
mechanism to screen the high-risk population for OPMD. It is of 
immense importance that diagnostic availability of novel 
biomarkers with high diagnostic and prognostic value and low-cost 
monitoring. Prevalence data of OPMD is also not significant enough 
as most of the studies are hospital-based. Real prevalence may differ 
in the general population in India. Large population based 
randomized case-control studies are required to obtain prevalence 
data. This data will definitely help to design new strategies of oral 
cancer prevention of National Cancer Control Program.  
OVERVIEW 
In India, oral cancer incidences continued to increase in young men 
and women. Currently, there are consencious for using marker that 
can be used for early detection and diagnosis of OSCC. Future 
research efforts in India aimed at Multicentric studies to identify the 
biomarker for early detection and diagnosis, and ultimately the 
survival of OSCC patients. It will generate the detail evidence of 
population based screening program in India and investigate the 
different ways of public awareness campaigns, practitioner 
education, and policy development to enhance the prevention of 
OSCC. The proposed theory of current knowledge will benefits to 
investigate the new ways to examine for high-risk populations for 
OSCC and educate them for oral health care. It will be the most 
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effective and appropriate ways of raising public awareness of OSCC 
and its risk factors. 
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